How to Counsel Cannabis Abstinence in PTSD With Cannabis Use Disorder
How should clinicians discuss and support a 12-week cannabis abstinence attempt in patients with comorbid PTSD and cannabis use disorder?
Patients with PTSD and cannabis use disorder often report using cannabis to self-manage distress, avoidance, and hyperarousal, yet this study found greater PTSD improvement with sustained abstinence than with nonabstinence. This guide applies to adults with DSM-5 PTSD and current CUD when clinicians are deciding whether abstinence should be part of treatment planning.
-
Identify patients with both PTSD and current CUD
Apply this workflow to adults with comorbid PTSD and cannabis use disorder rather than to PTSD alone. In the study, participants met DSM-5 criteria for current CUD and PTSD, and the findings were explicitly limited to this comorbid group.
-
Assess current cannabis use and recent exposure
Establish that the patient is using cannabis regularly or recently before discussing an abstinence trial. In the study, participants had a positive urine screen with THC-COOH of at least 150 ng/mL at baseline, a level described as consistent with regular consumption, recent consumption within the last 48 hours, or resumed use.
-
Explain the expected clinical rationale for abstinence
Discuss that in this 12-week study, sustained abstinence was associated with greater reductions in PTSD severity and total symptom count than nonabstinence. Among completers, CAPS-5 total scores decreased from 36.2 to 10.5 in abstinent participants versus 34.6 to 21.8 in nonabstinent participants, and symptom counts decreased from 14.3 to 4.1 versus 13.5 to 8.9.
-
Set a 12-week abstinence target with scheduled reassessment
Frame abstinence as a defined 12-week treatment trial rather than an open-ended request. Reassess PTSD symptoms at baseline and again at weeks 4, 8, and 12, which were the study timepoints used to track change with the CAPS-5.
-
Target counseling to symptom domains patients self-medicate
Tell patients that abstinence-related differences were strongest in avoidance and hyperarousal, symptoms many patients use cannabis to manage. In the study, abstinence was associated with significant time-by-group effects for Cluster C avoidance severity and Cluster E hyperarousal severity, while reexperiencing symptoms did not show a clear differential abstinence effect.
-
Provide brief weekly behavioral support early in the quit attempt
Use brief weekly individual sessions during the first 4 weeks that combine psychoeducation, motivational interviewing, and coping skills therapy. Early sessions in weeks 1 and 2 emphasized rapport and education about cannabis effects on psychiatric symptoms, while sessions in weeks 2 through 4 addressed coping strategies, relapse prevention, high-risk situations, cravings, and potential lapses.
-
Monitor withdrawal and anxiety during follow-up
Track cannabis withdrawal symptoms and anxiety while the patient attempts abstinence. The study measured withdrawal with a 16-item Marijuana Withdrawal Checklist and anxiety with the Beck Anxiety Inventory, and baseline withdrawal and anxiety differed between groups and were included as covariates in the analyses.
Clinical Considerations
- The findings are preliminary because the sample was small and the study used an open-label design.
- All participants received weekly study visits, weekly therapy support, and abstinence-contingent payments, so results may not generalize to usual care without these supports.
- The study population consisted of adults with comorbid PTSD and CUD and should not be generalized to patients with PTSD who do not have cannabis use disorder.
- Analyses were restricted to completers, so results may be biased if participants who discontinued differed in abstinence likelihood or symptom course.
Bottom Line
In adults with comorbid PTSD and cannabis use disorder, a structured 12-week cannabis abstinence trial belongs in treatment discussions because sustained abstinence was associated with larger PTSD symptom reductions than nonabstinence.
